Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropeginterferon alfa-2b in essential thrombocythaemia after intolerance, refractoriness, or ineligibility to other cytoreductive therapies
2023-505160-12-00Phase 3Authorised
- Sponsor
- AOP Health
- Start
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of ropeginterferon alfa-2b in thrombocythemia, sponsored by AOP Health. Primary endpoint: Rate of disease response at month 12 according to modified ELN criteria. Planned start Dec 2023; status: authorised.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
thrombocythemia
Beyond the preview
Go deeper on 2023-505160-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505160-12-00.